Farmaceutica R (RMAH) fair value: what the stock is really worth
As of Oct 16, 2026: fair value (intrinsic value) of Farmaceutica R stock RON 1.89, price RON 0.73, upside +158.2%, quality 55 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range 0.4206 RON – 0.9380 RON · fair‑value band 1.42 RON – 2.36 RON · the 0.7320 RON price screens below the 1.89 RON fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 3, 2026.
Follow Farmaceutica R in your weekly email
Every Wednesday you see whether Farmaceutica R is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Farmaceutica REMEDIA S.A. operates a chain of pharmacies in Romania. It is also involved in the wholesale distribution of medicines to pharmacies, and public and private hospitals and clinics.
Show moreShow less
In addition, the company provides packaging materials; and logistics and warehousing, promotion and marketing of drugs, and pharmaceutical products registration services. The company was incorporated in 1991 and is headquartered in Deva, Romania.
Stock analysis
Farmaceutica R (RMAH) currently trades at 0.7320 RON, while our model-based Fair Value estimate is 1.89 RON, implying the stock looks roughly 61.3% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 3.18 RON per share, and 19 of the 22 models we run sit above the 0.7320 RON price.
Bear case: the Asset-Based group reads lowest at 0.3000 RON, and 3 of the 22 models stay below the price. Data coverage for this calculation is low.
Scenario range: 1.42 RON (bear) to 2.36 RON (bull), the price of 0.7320 RON sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Farmaceutica R reported revenue of 760M RON in FY2025 versus 477M RON in FY2021, a compound +12.3%/yr. Reported net income was 8.0M RON in FY2025, compounding +2.7%/yr from FY2021.
Key figures
Market cap 68.6M RON (≈ $14.5M) · P/E ratio 18.3 · P/S ratio 0.19 · EPS (TTM) 0.0400 RON · Dividend yield 6.8% · Net margin 1.1% · Return on equity 6.2% · Return on assets (EBIT) 3.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (medium confidence).
What moves the price
The share trades about 22% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 34% fair-value upside, at 158%, RMAH screens cheaper than that median.
Fair Value models
Bear1.42 RONFair Value 1.89 RONBull2.36 RON
Price 0.7320 RON · Upside +158.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.5%
Start year 2020 (pandemic)
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−10.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−16.9%
Dividend (yield on the price)6.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 2%
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 76 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+158.2% · Top 25%
Profitability
Return on equity (12 months)6.2% · Below median
Return on assets2.1% · Below median
Net margin (12 months)0.5% · Below median
Operating margin (12 months)0.4% · Bottom 25%
Growth and dividend
Revenue growth0.3% · Below median
Dividend yield (12 months)6.8% · Top 25%
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Farmaceutica R Fair Value". https://www.fairvalue-calculator.com/stock/RMAH
Frequently asked questions
Is Farmaceutica R (RMAH) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 1.89 RON versus a price of 0.7320 RON, about +158% upside (undervalued).
What is the fair value of RMAH?
Our model-based fair value for Farmaceutica R is 1.89 RON (as of Oct 3, 2026), built from audited fundamentals. The current price: 0.7320 RON.
What is the quality score of RMAH?
Farmaceutica R has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Farmaceutica R (RMAH)?
Our model-based price target is the fair value of 1.89 RON (as of Oct 3, 2026) from 22 valuation models. Cautious scenario 1.42 RON, optimistic scenario 2.36 RON. It is a calculation from audited fundamentals, not an analyst target.
What is the Farmaceutica R stock forecast for 2026?
Our models put fair value at 1.89 RON, about +158% upside versus a price of 0.7320 RON (undervalued). Cautious scenario 1.42 RON, optimistic scenario 2.36 RON. The calculation is refreshed regularly with new filings.
What is the revenue of Farmaceutica R (RMAH)?
Farmaceutica R reported trailing-twelve-month revenue of about 740M RON (latest available figure, as of Oct 3, 2026).
Does Farmaceutica R pay a dividend?
Farmaceutica R currently shows a dividend yield of 6.83% relative to its recent price (as of Oct 3, 2026).
What growth is priced into Farmaceutica R (RMAH)?
For today's price to be fair in a discounted-cash-flow model, Farmaceutica R would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.5 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of RMAH use?
Our models discount Farmaceutica R at 10.9 %: a base by market capitalisation (nano), damped by beta 0.07, country premium for Romania. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Farmaceutica R that is less than minus 40 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Farmaceutica R (RMAH) delivered so far?
Over the past 5 years revenue at Farmaceutica R grew +11.5 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Farmaceutica R (RMAH) growing?
The median revenue growth in the sector is +0.0 % a year. That is the yardstick for the growth priced into Farmaceutica R (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Farmaceutica R (RMAH)?
The free-cash-flow yield on the price is 22.66 %: that much free cash flow Farmaceutica R produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Farmaceutica R (RMAH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Farmaceutica R it is 1.89 RON per share (as of Oct 3, 2026), against a price of 0.7320 RON. It is the blended result of 22 valuation models (cash flow, earnings, asset, dividend).
Is Farmaceutica R stock overvalued or undervalued in 2026?
As of Oct 3, 2026, RMAH trades below its calculated fair value: price 0.7320 RON, fair value 1.89 RON, a gap of about +158% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RMAH?
No. The price is what the market pays today (0.7320 RON); the fair value is what the company's own numbers justify (1.89 RON). For Farmaceutica R the two are 1.16 RON per share apart. That gap is exactly why we show both numbers side by side.
How much is Farmaceutica R worth?
The market values Farmaceutica R at about 68.6M RON (market capitalisation, as of Oct 3, 2026). Per share that is 0.7320 RON; our models calculate a fair value of 1.89 RON per share.
What do the bullish and bearish scenarios say about RMAH?
Our models span a range for Farmaceutica R: cautious scenario 1.42 RON, base 1.89 RON, optimistic 2.36 RON per share (as of Oct 3, 2026, price 0.7320 RON). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RMAH?
Farmaceutica R trades at a price-to-earnings ratio of 18.3 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 1.89 RON is built from several models across several years. Other multiples: P/B 0.9, P/S 0.1, EV/EBITDA 1.1.
How solid is the balance sheet of Farmaceutica R (RMAH)?
Balance-sheet figures for Farmaceutica R (as of Oct 3, 2026): return on equity 6.2%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is RMAH from its 52-week high?
Farmaceutica R trades at 0.7320 RON, about 22% below its 52-week high of 0.9380 RON and 6% above the low of 0.6920 RON (as of Oct 16, 2026). Distance from the high says nothing about value: that is what the fair value of 1.89 RON is for.
Which stocks are comparable to Farmaceutica R?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Farmaceutica R stock attractive at the current price?
The data as of Oct 3, 2026: price 0.7320 RON, calculated fair value 1.89 RON (+158%), Quality Score 55/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RMAH calculated?
We run Farmaceutica R through 22 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1.89 RON, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7 % above its aggregate fair value. Farmaceutica R currently trades 61 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Farmaceutica R (RMAH)?
The closing price on Oct 16, 2026 was 0.7320 RON. Our model-based fair value is 1.89 RON, about +158% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Farmaceutica R right now?
The price is below even our cautious bear case (1.42 RON). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Farmaceutica R
How large is the market capitalisation of Farmaceutica R (RMAH)?
The market capitalisation of Farmaceutica R is 68.6M RON (≈ $14.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Farmaceutica R (RMAH)?
The price-to-sales ratio of Farmaceutica R is 0.19 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Farmaceutica R (RMAH)?
Earnings per share at Farmaceutica R are 0.0400 RON (price ÷ EPS = P/E 18.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Farmaceutica R (RMAH)?
The dividend yield of Farmaceutica R is 6.8% (payout 125%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Farmaceutica R (RMAH)?
The net margin of Farmaceutica R is 1.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Farmaceutica R (RMAH)?
The return on equity (ROE) of Farmaceutica R is 6.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Farmaceutica R (RMAH)?
On an EBIT basis the return on assets of Farmaceutica R is 3.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Farmaceutica R (RMAH)?
The operating margin of Farmaceutica R is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Farmaceutica R (RMAH)?
Revenue at Farmaceutica R is growing +0.3% versus a year earlier (3y avg +12.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Farmaceutica R (RMAH)?
Earnings per share at Farmaceutica R are growing −80.3% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Farmaceutica R in the live analysis
One click puts Farmaceutica R on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
Thin data
Oct 3, 2026